Association of oncostatin M receptor polymorphisms with clinical recurrence of ovarian cancer in the Chinese Han population

Biomark Med. 2022 Apr;16(6):461-471. doi: 10.2217/bmm-2021-0989. Epub 2022 Mar 24.

Abstract

Aim: Ovarian cancer (OC) is a gynecological malignancy with a challenging judgment of prognosis due to complicated etiology and high recurrence rate. The oncostatin M receptor (OSMR) from members of the IL-6 receptor family is associated with tumor development. This study aims to explore the correlations between OSMR gene polymorphisms (rs2278329 [G/A, missense, Asp553Asn], rs2292016 [G/T, promoter, -100G/T]) and OC. Methods: This study enrolled 160 OC patients and 397 healthy controls. Genotypes of two single-nucleotide polymorphisms were distinguished using TaqMan SNP Genotyping Assay, and statistical analysis was performed using SPSS software. Results: A significantly decreased overall survival rate was found in serous OC patients carrying rs2278329 GA/AA genotypes. Meanwhile, TT genotype carriers of rs2292016 had an improved relapse rate, and the GT genotype showed a definitive correlation with a lower relapse rate. Conclusion:OSMR gene polymorphisms may be related to recurrence and overall survival of serous OC patients.

Keywords: STAT3; genetic polymorphisms; oncostatin M receptor; ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Ovarian Epithelial
  • Case-Control Studies
  • China / epidemiology
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Neoplasm Recurrence, Local* / genetics
  • Ovarian Neoplasms* / genetics
  • Ovarian Neoplasms* / pathology
  • Polymorphism, Single Nucleotide
  • Receptors, Oncostatin M / genetics

Substances

  • Receptors, Oncostatin M